Skip to main content
. 2017 Apr 20;8(32):52527–52542. doi: 10.18632/oncotarget.17283

Figure 6. Comparison of cell proliferation among the blank, miR-126 mimics, miR-126 inhibitors, miR-126 inhibitors + siRNA EGFL7, mimics control, and inhibitors control groups after transfection.

Figure 6

(A). the proliferation of HepG2 cells among the blank, miR-126 mimics, miR-126 inhibitors, miR-126 inhibitors + siRNA EGFL7, mimics control and inhibitors control groups after transfection; (B). the proliferation of Bet-7402 cells among the blank, miR-126 mimics, miR-126 inhibitors, miR-126 inhibitors + siRNA EGFL7, mimics control and inhibitors control groups after transfection; (C). the proliferation of smmc-7721 cells among the blank, miR-126 mimics, miR-126 inhibitors, miR-126 inhibitors + siRNA EGFL7, mimics control and inhibitors control groups after transfection; *P < 0.05 compared with the blank group; miR-126, microRNA-126; EGFL7, epidermal growth factor-like domain 7.